

WHO Prequalification Programme / Vector Control Product Assessment

# WHO Public Assessment Report: WHOPAR Part 5

# Yorkool G5 LN (Tianjin Yorkool International Trading Co., Ltd)

P-12507

# **Efficacy Assessment**





#### Contents

1	Introduction	3
2	Semi-field studies	3
	2.1 Semi-field studies	3
	2.2 Chemical characterization	8
	2.3 Semi-field studies conclusions	9
3	Efficacy conclusions	9



## 1 Introduction

The primary purpose for the use of a pesticide is the control of a pest, including disease transmitting vectors. Vector control tools, including formulated pesticides, which provide effective management or control of vectors, may be used as part of a resistance management programme. Vector control products for use in public health are a component of Integrated Vector Management (IVM), which is a programme that relies on a suite of diverse interventions and implementations of best practices to manage the vector and chemical/behavioural resistance.

Yorkool G5 is a homogenous ITN coated with 2.4 g AI/kg alpha-cypermethrin and 4.8 g AI/kg chlorfenapyr that is intended to provide personal and community protection from Anopheline mosquitoes as part of malaria control programmes.

Semi-field studies to characterize the performance of Yorkool G5 against free-flying mosquitoes with supplementary bioassays to characterize the availability of active ingredients and insecticidal effect of the fabric of the ITN on Anopheline mosquito species were submitted to WHO as part of the prequalification dossier.

### 2 Semi-field studies

Studies conducted in semi-field settings often include the investigation of endpoints other than mortality, knockdown and blood-feeding inhibition. Examples of these include entry rate, exit rate, and deterrence, as well as analyses for non-standardized calculations of "personal protection". Based on the existing requirements and established decision framework, mosquito mortality and knockdown are considered the primary endpoints for assessment. Therefore, results for these are included within the summaries of these studies. Calculations of blood feeding inhibition were also included for further characterization of the entomological impact of the product.

#### 2.1 Semi-field studies

Data on the semi-field performance of Yorkool G5 were provided. These data were obtained from studies conducted according to established standards and/or Good Laboratory Practices (GLP). These summary results are based on ITNs drawn from batches 20211013, 20211108 and 20211203.

Two semi-field studies were presented to evaluate the efficacy and wash resistance of Yorkool G5 in Benin and Tanzania. Both semi-field studies that were conducted were experimental hut trials (EHTs). ITNs used in semi-field studies were prepared using a wash interval of five days that was selected based on the results from the Module 3 laboratory studies. The endpoint used to evaluate bioavailability was 72-hour mortality. The negative control used in each study was an untreated net. The positive controls used in the semi-field studies were a prequalified ITN product treated with 2.4 g AI/kg alphacypermethrin and 4.8 g AI/kg chlorfenapyr, hereafter referred to as PC1, a prequalified ITN product treated with 5.0 g AI/kg alpha-cypermethrin, hereafter referred to as PC2, and a prequalified ITN product treated with 4.5 g AI/kg alpha-cypermethrin, hereafter referred to as PC3. In non-inferiority analyses conducted on the results of the semi-field studies, PC1 was used as an active comparator; PC2 and PC3 were used as standard comparators.

The product was tested against pyrethroid resistant natural populations of, in Covè, Benin, *An. coluzzi* and *An. gambiae* s.s, with the relative proportions estimated at 77% and 23%, respectively. The pyrethroid resistance is mediated by *kdr*, with the *An. gambiae* s.l population carrying *kdr* gene frequencies of >90% L1014F and an intensity of resistance of greater than 200-fold the diagnostic dose, and metabolic resistance through over-expression of CYP6P3 enzymes. In resistance testing conducted during the EHT, 16% and 98% mortality were observed following exposure to the diagnostic doses of alpha-cypermethrin and chlorfenapyr, respectively. In resistance intensity testing conducted using 10x the diagnostic dose of alpha-cypermethrin, 40% mortality was observed.

In the semi-field study conducted in Tanzania, the product was tested against pyrethroid resistant natural populations of the *An. gambiae* complex, of which >99.9% was *An. arabiensis*. In resistance testing conducted prior to the EHT, 13% mortality was observed following exposure to the diagnostic dose of alpha-cypermethrin. Resistance testing using the diagnostic dose of chlorfenapyr was not conducted.

The results from the free-flying mosquito studies are presented in Table 1. Yorkool G5 ITNs that were washed 20 times using a 5-day wash interval induced 50.3% 72-hour mortality in wild free-flying *An. gambiae* s.l. mosquitoes in Benin and 34.6% 72-hour mortality in free-flying *An. arabiensis* mosquitoes in Tanzania, respectively. Non-inferiority statistical analyses demonstrated that, following 20 washes using a five-day wash interval, Yorkool G5 was non-inferior to PC1 and superior to PC2 and PC3 for the mortality endpoint in both semi-field study locations (Table 2).

Supplementary bioassays were used to characterize the bioavailability of the active ingredients on the surface of the ITN pre- and post-hut studies using unwashed and 20x washed nets. WHO cone tests and tunnel tests were the experimental methods used in bioavailability studies. In Benin, tunnel tests using the insecticide susceptible *An. gambiae* s.s. Kisumu test system and the pyrethroid resistant *An. gambiae* s.l. Covè test system were used to evaluate bioavailability. In Tanzania, WHO cone tests and tunnel tests were conducted using the insecticide susceptible *An. gambiae* Ifakara test system (cone tests) and the pyrethroid resistant *An. arabiensis* Kingani test system (tunnel tests) for bioavailability evaluations. Thresholds of  $\geq$ 95% knockdown and/or  $\geq$ 80% mortality in WHO cone tests and  $\geq$ 80% mortality or  $\geq$ 90% blood feeding inhibition in tunnel tests were used as the efficacy criteria for bioavailability. The endpoint used to evaluate bioavailability was 72-hour mortality.

The results from supplementary bioassays are presented in Table 3. In tunnel tests conducted using insecticide susceptible and pyrethroid resistant test systems, greater than 80% mortality was observed at 72 hours post-exposure using unwashed and 20x washed nets, before and after the EHT in Benin. In Tanzania, greater than 80% mortality in tunnel tests conducted using a pyrethroid resistant test system was observed in tests conducted using unwashed nets before and after the EHT. The observed mortality in 20x washed nets was 33.8% before the EHT and 72.7% after the EHT. The increase in the observed mortality for 20x washed nets between the start and the end of the EHT in Tanzania may indicate that later in the life of the product, a wash interval longer than five days is required for full bioavailability of the AI on the surface of the fabric.



Table 1. Mortality and Blood Feeding Inhibition of Wild, Free-Flying Pyrethroid Resistant An. gambiae s.l.	and <i>An. arabiensis</i>
in Experimental Hut Trials in Benin and Tanzania	

Product	Washing condition	% M72 (95% CI)	% Feeding inhibition (95% CI)	Sample Size				
Benin (An.gambiae s.l)								
Total number of mosquitoes collected = 6,761 Compliant with power calculation? Yes								
Control	Unwashed	0.7 (0.2 – 1.2)	-	1,187				
Varkool G5	Unwashed	59.3 (55.4 – 63.2)	33.3 (29.6 – 37.0)	612				
Torkoor do	20x washed	50.3 (47.5 – 53.1)	18.2 (16.0 – 20.4)	1,217				
DC1	Unwashed	60.6 (56.6 – 64.6)	32.0 (28.1 – 35.7)	581				
PCI	20x washed	48.8 (45.7 – 51.9)	18.7 (16.3 – 21.1)	1,026				
DC3	Unwashed	15.3 (12.8 – 17.8)	24.9 (21.9 – 27.9)	780				
PCZ	20x washed	12.2         6.7           (10.5 - 13.9)         (5.4 - 8.0)		1,358				
Tanzania (An.arabiensis)								
Total	number of mosquitoes colle	cted = 22,100	Compliant with power c	alculation? Yes				
Control	Unwashed	0.7	-	4,461				
N L LOS	Unwashed*	41.9 (38.1 – 45.7)	96.4 (95.1 – 97.7)	1,516				
Yorkool G5	20x washed*	34.6 (31.8 – 37.4)	95.2 (94.0 – 96.4)	3,323				
DC1	Unwashed*	43.4 (39.4 - 47.4)	97.2 (95.9 – 98.4)	1,095				
PC1	20x washed*	34.5 (31.6 – 37.4)	95.8 (94.3 – 97.4)	2,790				
PC3	Unwashed*	27.6 (24.4 – 30.8)	96.8 (96.0 – 97.7)	4,501				
rts	20 1 1*	27.3	96.5					

(24.6 - 29.9)

\* Control-corrected mortality

20x washed\*

(95.5 - 97.5)

4,414



able 2. Non-inferiority analysis for Yorkool G5 in experimental huts using wild, pyrethroid-resistant Anopheles gambiae s.l. mosquitoes in Covè, Southern Benin and wild, pyrethroid resistant An. arabiensis mosquitoes in Lupiro,															
	Unwashed							20x washed			Pooled				
Indicator and reference	Target Outcome	Non- inferiority margin	OR (95% CI)	р	Interpretation	Target Outcome	Non- inferiority margin	OR (95% CI)	р	Interpretation	Target Outcome	Non- inferiority margin	OR (95% CI)	р	Interpretation
							Benii	ı							
M72 PC1 (active comparator)	Non-inferiority	0.751	0.93 ( <b>0.71</b> -1.20)	NA	Not non-inferior	Non-inferiority	0.753	1.02 ( <b>0.84</b> -1.23)	NA	Non-inferior	Non-inferiority	0.755	0.983 ( <b>0.84</b> -1.15)	NA	Non-inferior
M72 PC2 (standard comparator)	Superiority	NA	10.92 (8.20 – 14.53)	<0.001	Superior <sup>a</sup>	Superiority	NA	8.93 (7.12 – 11.18)	<0.001	Superior	Superiority	NA	9.75 (8.14-11.68)	<0.001	Superior
Blood feeding rate PC1 (active comparator)	Non-inferiority	1.328	1.09 (0.84- <b>1.40</b> )	NA	Not non-inferior	Non-inferiority	1.325	1.06 (0.88- <b>1.28</b> )	NA	Non-inferior	Non-inferiority	1.324	1.08 (0.93- <b>1.26</b> )	NA	Non-inferior
Blood feeding rate PC2 (standard comparator)	Superiority	NA	0.81 (0.64 – 1.03)	0.087	Not superior	Superiority	NA	0.70 (0.59 – 0.84)	<0.001ª	Superior	Superiority	NA	0.74 (0.64 - 0.85)	<0.001	Superior
	Tanzania														
M72 PC1 (active comparator)	Non-inferiority	0.75	0.98 ( <b>0.83</b> , 1.16)	NA	Non-inferior	Non-inferiority	0.73	1.01 ( <b>0.90</b> , 1.13)	NA	Non-inferior	Non-inferiority	0.74	1.01 ( <b>0.92</b> , 1.11)	NA	Non-inferior
M72 PC3 (standard comparator)	Superiority	NA	2.03 (1.79, 2.30)	<0.0001	Superior	Superiority	NA	1.54 (1.38, 1.71)	<0.000 1	-	Superiority	NA	1.73 (1.60, 1.88)	<0.0001	Superior
Blood feeding rate PC1 (active comparator)	Non-inferiority	3.59	1.21 (0.76, <b>1.94</b> )	NA	Non-inferior	Non-inferiority	2.97	1.34 (1.03, <b>1.75</b> )	NA	Non-inferior	Non-inferiority	2.97	1.30 (1.03, <b>1.63</b> )	NA	Non-inferior
Blood feeding rate PC3 (standard comparator)	Superiority	NA	1.12 (0.80, 1.56)	0.523	Not superior	Superiority	NA	1.55 (1.22, 1.98)	<0.000 1	Inferior	Superiority	NA	1.38 (1.14, 1.67)	0.001	Inferior

NA = Not applicable, NR = Not reported, non-inferiority margin representing a 7% difference in proportion,

WHO Prequalification of Vector Control Products Avenue Appia 20 1211 Geneva 27 Cwittageland For further information, contact:

pqvectorcontrol@who.int

https://extranet.who.int/pregual/vector-control-product



Table 3. Knockdown, me	ortality and b	lood feeding inhil	bition results for i	nsecticide susc	eptible and pyret	hroid resistant		
laboratory strains using	WHO cone b	ioassays and tunr	nel tests					
		Benin		Benin				
		An. gambiae Kisu	umu	An. gambiae Covè				
	n	%M72	%BFI	n	%M72	%BFI		
		(95% CI)	(95% CI)		(95% CI)	(95% CI)		
		Be	efore hut trial					
11147	100	100.0	97.8	217	96	94.2		
UW	196	(96 - 100)	(95.8 – 99.9)	217	(93 – 99)	(91.1 – 97.3)		
20u una chia d	200	98.5	92.3	107	93	72.3		
20x washed	206	(97 - 100)	(88.7 – 95.9)	197	(89 – 96)	(66.1 – 78.6)		
		Α	After hut trial					
1.0.47	24.0	99.0	98.5	200	98	91.7		
UW	210	(98 – 100)	(96.9 – 100)	208	(96 – 99)	(87.9 – 95.5)		
20	205	97.6	95.9	100	98	87		
20x washed		(95 – 100)	(93.2 – 98.6)	189	(96 - 100)	(83 – 92.4)		
Tanzania								
	An. gambiae Ifakara An. arabiensis Kingani							
		%KD60	%M72		%M72	%BFI		
	n	(95% CI)	(95% CI)	n	(95% CI)	(95% CI)		
		В	efore hut trial	·	·			
1.15.47	200	100	55.7	200	94.4	99.3		
UW	300	100	(49.0 – 62.3)	300	(84.2 – 100)	(97.7 – 100)		
		400	43.6	200	33.8	97.0		
20x washed	300	100	(38.2 – 49.0)	298	(24.7 – 42.8)	(92.9 – 100)		
			After hut trial					
11147	200	100	51.0	107	88.6	100		
UW	200	100	(41.3 – 60.7)	197	(76.6 – 100)	100		
20	200	100	38.0	100	72.7	100		
20x washed	200		(31.1 - 44.9)	196	(64.1 - 81.4)	100		

#### 2.2 Chemical characterization

Data on the alpha-cypermethrin and chlorfenapyr content of sampled pieces of the Yorkool G5 LN product used in the semi-field studies were provided. These data were obtained from studies conducted according to established standards and/or Good Laboratory Practices (GLP). These summary results are based on ITNs drawn from batches 20211013, 20211108 and 20211203. The results are summarized in Table 4.

 Table 4. Al content and retention of sampled pieces of Yorkool G5 used in the semi-field studies in Benin and Tanzania (batch numbers 20211013, 20211108 and 20211203 - used in both locations)

		Beni	n		Tanza	nia		
	Mean alpha- cypermethrin content (g/kg)	Alpha- cypermethrin retention (per wash)	Mean chlorfenapyr content (g/kg)	Chlorfenapyr retention (per wash)	Mean alpha- cypermethrin content (g/kg)	Alpha- cypermethrin retention (per wash)	Mean chlorfenapyr content (g/kg)	Chlorfenapyr retention (per wash)
	-			Before hut tria	I	-	-	-
UW	2.40	-	4.00	-	2.43	-	4.16	-
20x washed	1.40	58.33% (97.34%)	2.10	52.50% (96.83%)	1.19	48.97% (96.49%)	2.45	58.89% (97.39%)
		After hut trial			After hu	t trial		
UW	2.00	-	3.60	-	2.38	-	3.78	-
20x washed	1.4	70.00% (98.23%)	2	55.56% (97.10%)	1.25	52.52% (96.83%)	2.28	60.32% (97.50%)

For Tanzania, the mean AI content presented in Table 4 was determined based on 15 net samples for unwashed (UW) product and after 20 washes before hut trial and 10 net samples for unwashed (UW) product and after 20 washes after hut trial, all belonging to 3 batches (20211013, 20211108 and 20211203).

For Benin, the mean AI content presented in Table 4 was determined based on 5 net samples belonging to 3 batches (20211013, 20211108 and 20211203) for unwashed (UW) product and after 20 washes before hut trial and after hut trial.

Al retention per wash in Table 4 is calculated as:

- Al retention per wash =  $100 \text{ x} \text{ }^{\text{n}}\text{V}(t_n/t_0)$  where:
  - $\circ$  t<sub>n</sub> = total active ingredient content after n washing cycles
  - t<sub>0</sub> = total active ingredient content before washing
  - n = number of washes.

The chemical analysis performed on samples of ITNs used in the semi-field studies confirmed that the test samples conformed with the batch analysis data presented in Module 3 and that the test samples were appropriate for use in the study.

The AI content for the unwashed product complied with the target dose interval limits in the specification (i.e., 2.4 g/kg + 25% - 15% for alpha-cypermethrin,  $4.8 \pm 25\%$  g/kg for chlorfenapyr).



#### 2.3 Semi-field studies conclusions

The submitted semi-field studies demonstrate the impact of Yorkool G5 LN on free-flying mosquitoes and the bioavailability of the treatments on the ITN fabric using WHO cone bioassays and tunnel tests. Based on the submitted studies, the impact of Yorkool G5 LN ITNs that have been prepared using a 5-day wash interval can be sustained against pyrethroid resistant and insecticide susceptible free-flying mosquitoes up to 20 washes. The bioavailability of the treatments on the Yorkool G5 LN fabric was sustained up to 20 washes against insecticide susceptible test systems of the *An. gambiae* and *An. arabiensis*.

### 3 Efficacy conclusions

Based on the studies and information provided, all data requirements for the prequalification assessment of product efficacy have been satisfied. These data have been relied upon to assess the bioavailability and the impact on free-flying mosquitoes of the proposed product for the purpose of characterising the fabric of the product and establishing the duration of biological impact using products prepared with a defined wash interval.

The efficacy component of the dossier is considered complete, and the assessment of the submitted information on efficacy supports prequalification of the product.

Table 5. List of efficacy studies submitted to WHO as part of the prequalification dossier							
Studies that were relied upon for decision making							
Study number Study title							
	Experimental hut evaluation of the efficacy and wash resistance of Yorkool® G5 (a new						
22-04	alphacypermethrin and chlorfenapyr mixture bed nets by Tianjin Yorkool International Trading Co.,						
	Ltd) against wild, pyrethroid-resistant Anopheles gambiae sl in Covè, Southern Benin						
	The non-inferiority evaluation of Yorkool G5 Insecticide treated nets in comparison to Interceptor G2						
BITU80 WPZ	and MiraNet in the experimental huts against wild mosquitoes in Tanzania.						
TE2023-032	Chemical analysis of Yorkool G5 LN IHI Phase 2 experimental hut study						
TE2023-004	Chemical analysis of Yorkool G5 LN experimental hut study						
Studies that were not used to inform decision making							
	None						